

Drug Monograph

Drug/Drug **Abilify Maintena™ (aripiprazole) extended release**

Class: **injection/ atypical antipsychotic**

Prepared for: MO HealthNet

Prepared by: Xerox Heritage, LLC

New Criteria

Revision of Existing Criteria

Executive Summary

Purpose:	The purpose of this monograph is to provide a review of new therapy to determine whether the reviewed drug should be made available on an open access basis to prescribers, require a clinical edit or require prior authorization for use.
Dosage Forms:	Abilify Maintena™ for extended release is available in 400mg/vial and 300mg/vial powder for reconstitution.
Manufacturer:	Otsuka America Pharmaceutical, Inc., Rockville, MD 20850
Indications:	Abilify Maintena™ extended release injection is an atypical antipsychotic approved for the treatment of schizophrenia.
Costs:	\$1098.88 and \$1464.50 per vial of 300mg/vial and 400mg/vial strengths of Abilify Maintena™ respectively. MoMAC
Summary of Findings:	The Division recommends this product be added to the existing Atypical Antipsychotic and Polypharmacy Clinical Edits.
Status Recommendation:	<input type="checkbox"/> Prior Authorization (PA) Required <input type="checkbox"/> Open Access <input checked="" type="checkbox"/> Clinical Edit <input type="checkbox"/> PDL
Type of PA Criteria:	<input type="checkbox"/> Increased Risk of ADE <input type="checkbox"/> Non-Preferred Agent <input checked="" type="checkbox"/> Appropriate Indications <input type="checkbox"/> Under Solicitation

Prepared By: Kathleen Wilbers, Pharm.D.

Date: May 28, 2013